Mangoceuticals Sees Zero Respiratory Mortality in 29,000-Bird Trial and 60% H5N1 Death Reduction
Mangoceuticals' antiviral compound MGX-0024 delivered via drinking water in three independent field trials on 29,000 broilers resulted in zero respiratory-related mortality, versus an expected ~50% death rate (~14,500 birds) in untreated flocks. A BSL-3 lab challenge study showed MGX-0024 pre-treatment reduced H5N1 mortality by up to 60% and extended mean time to death from 5.86 to 10.71 days.
1. Zero Mortality in 29,000-Bird Field Trials
In three independent commercial trials on farms in Tamil Nadu, India, approximately 29,000 broiler chickens received MGX-0024-infused drinking water from day 14 through market age. No respiratory-related deaths occurred, contrasting with historical and neighboring untreated flocks reporting about 50% mortality (~14,500 birds) due to viral or bacterial infections.
2. Controlled H5N1 Challenge Demonstrates Prophylactic Benefit
Under BSL-3 conditions, specific-pathogen-free chicks pre-treated with MGX-0024 for 48 hours showed a 60% reduction in mortality (2 of 7 deaths versus 5 of 7 in controls) following a 10⁵ EID₅₀ H5N1 intranasal challenge. Treated birds also exhibited extended mean survival time (10.71 days versus 5.86 days) and low viral shedding.
3. Scaling Production and Regulatory Engagement
Mangoceuticals is scaling production and refining logistics for key markets like India, with distribution interest from farms and agencies. The company and partner IntraMont are pursuing regulatory discussions in the US, UK, Canada, and Australia, and planning further multi-farm studies and grant applications to support commercial rollout.